Atopic dermatitis ameliorating agent, interleukin production inhibitor, and interleukin gene expression inhibitor

By using glycerol ascorbic acid acylated derivatives in atopic dermatology ameliorate agents, the production and gene expression of interleukin 33 and interleukin 1 are inhibited, and the poor effect of atopic dermatology ameliorate agents in the prior art is solved. The problem of this has achieved effective improvement of atopic skin diseases.

CN118946351APending Publication Date: 2024-11-12PIAS ARISE KK
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380029913.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-03-28
Filing Date
2023-03-08
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The existing atopic dermatological disease improvers have not been fully studied and cannot effectively improve the symptoms of atopic dermatological diseases, especially the production of interleukin and gene expression inhibition.

Method used

Atopic dermatitis improver containing glycerol ascorbic acid acylated derivatives is used to inhibit the production and gene expression of interleukin 33 and interleukin 1, specific compounds such as 2-O-glycerol-6-hexadecanoyl ascorbic acid Atopic skin disease is improved by inhibiting the production of inflammatory stimulators in epidermal cells.

Benefits of technology

Effectively inhibit the production and gene expression of interleukin 33 and interleukin 1, reduce the inflammatory response of atopic skin diseases, improve the skin pathological status, and provide a more effective treatment plan.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118946351A_ABST
    Figure CN118946351A_ABST
Patent Text Reader

Abstract

The present invention provides an atopic dermatitis ameliorating agent and the like containing a glyceroascorbic acid acylated derivative having a specific molecular structure.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Cross-reference to related applications:

[0002] This application claims the benefit of Japanese Patent Application No. 2022-051537, which is hereby incorporated by reference into the specification of the present application. Technical Field

[0003] The present invention relates to an atopic dermatitis improving agent, an interleukin production inhibitor, and an interleukin gene expression inhibitor. Background Art

[0004] Atopic dermatitis is a chronic disease in which eczema accompanied by itching repeatedly worsens and improves, and is believed to be caused by a complex interaction of multiple causes. For example, the production of lipid mediators that induce allergic reactions is believed to exacerbate atopic dermatitis, but it is not considered to be the only cause of atopic dermatitis.

[0005] Conventionally, various atopic dermatitis-improving agents for improving the above-mentioned atopic skin diseases are known.

[0006] As this type of atopic dermatitis improving agent, for example, an ointment containing docosahexaenoic acid (DHA) and / or eicosapentaenoic acid (EPA) and an ointment containing tacrolimus are known (Patent Document 1).

[0007] The atopic dermatitis improving agent described in Patent Document 1 can suppress the production of leukotriene B4, which is one of the lipid mediators inducing allergic reactions, thereby improving the symptoms of atopic skin diseases.

[0008] Prior art literature:

[0009] Patent Literature

[0010] Patent document 1: Japanese Patent Publication No. 2017-197471. Summary of the invention

[0011] Problems to be solved by the present invention

[0012] However, agents that can improve atopic skin diseases have not been fully investigated.

[0013] Therefore, an object of the present invention is to provide an atopic dermatitis improving agent, an interleukin production inhibitor, and an interleukin gene expression inhibitor that can improve atopic skin diseases.

[0014] Means of solving the problem

[0015] The atopic dermatitis improving agent of the present invention is characterized by comprising a glycerol ascorbic acid acylated derivative represented by the following formula (I).

[0016]

[0017] The interleukin production inhibitor of the present invention contains the glycerol ascorbic acid acylated derivative represented by the above formula (I) and is used for inhibiting the production of interleukin-33 and interleukin-1.

[0018] The interleukin gene expression inhibitor of the present invention contains the glycerol ascorbic acid acylated derivative represented by the above formula (I), and is used for inhibiting the expression of interleukin 33 and interleukin 1 genes. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] Figure 1 It is a graph showing the test results (in vitro test) evaluating the effect on interleukin 33 (IL-33) gene expression.

[0020] Figure 2 It is a graph showing the test results (in vitro test) for evaluating the effect on interleukin 1 alpha (IL-1 alpha) gene expression.

[0021] Figure 3 It is a graph showing the test results (in vitro test) for evaluating the effect on interleukin 1 beta (IL-1 beta) gene expression.

[0022] Figure 4 It is a graph showing the test results (in vitro test) evaluating the effect on interleukin 33 (IL-33) gene expression.

[0023] Figure 5 It is a graph showing the test results (in vitro test) for evaluating the effect on interleukin 1 alpha (IL-1 alpha) gene expression.

[0024] Figure 6 It is a graph showing the test results (in vitro test) for evaluating the effect on interleukin 1 beta (IL-1 beta) gene expression. DETAILED DESCRIPTION

[0025] Hereinafter, one embodiment of the atopic dermatitis improving agent, interleukin production inhibitor, and interleukin gene expression inhibitor (hereinafter also referred to as preparation) of the present invention will be described.

[0026] The preparation of the present embodiment contains a glycerol ascorbic acid acylated derivative represented by the following formula (I).

[0027]

[0028] Since the preparation of the present embodiment contains the glycerol ascorbic acid acylated derivative represented by the above formula (I), it can exert an action of suppressing the production of specific inflammatory cytokines associated with atopic skin diseases, thereby improving atopic skin diseases.

[0029] The compound represented by the above formula (I) is also called 2-O-glycerol-6-hexadecanoyl ascorbic acid.

[0030] 2-O-glycerol-6-acetyl ascorbic acid, 2-O-glycerol-6-butyryl ascorbic acid, 2-O-glycerol-6-octanoyl ascorbic acid (2-O-glycerol-6-(2-ethylhexanoyl) ascorbic acid), 2-O-glycerol-6-tetradecanoyl ascorbic acid, 2-O-glycerol-6-octadecanoyl ascorbic acid, or 2-O-glycerol-6-docosacorbic acid, which are similar to the compound represented by the above formula (I), may not necessarily fully improve atopic skin diseases.

[0031] Since the preparation of this embodiment contains the glycerol ascorbic acid acylated derivative represented by formula (I), the production of cytokines caused by inflammatory stimulation of epidermal cells can be inhibited. For example, the production of specific cytokines such as interleukin 33 (IL-33) and interleukin 1 (IL-1α or IL-1β) can be inhibited. In this way, atopic skin diseases can be improved.

[0032] Interleukin 33 (IL-33) is a cytokine involved in the pathology of allergic diseases. Among skin allergic diseases, it is a cytokine that worsens the pathology of atopic dermatitis. Specifically, interleukin 33 (IL-33) is a cytokine produced by epidermal cells and is overexpressed in the epidermal cells of patients with atopic dermatitis. Specifically, interleukin 33 (IL-33) activates Th2 cells of helper T cells and type 2 innate lymphocytes (ILC2), inducing Th2 cytokines such as interleukin 4 (IL-4) and interleukin 13 (IL-13), thereby causing a type 2 inflammatory response that is mainly atopic dermatitis.

[0033] Interleukin 1 (IL-1) is an inflammatory cytokine involved in a variety of inflammatory conditions and is also a cytokine involved in the pathological exacerbation of atopic dermatitis. For example, interleukin 1 (IL-1) is produced by epidermal cells in response to various stimuli and causes inflammation. The IL-1 receptor on mature helper T cells is only present on Th2 cells. IL1 causes Th2 cells to proliferate, which can cause or aggravate atopic dermatitis.

[0034] Since the agent of this embodiment can inhibit the expression of the above-mentioned inflammatory cytokine genes produced by epidermal cells, it is also an inhibitor of the gene expression of IL-33, IL-1α and IL-1β.

[0035] The compound represented by the above formula (I) can be synthesized by the following synthesis method described in Japanese Patent Laid-Open No. 2011-079772, for example.

[0036] (Intermediate: Synthesis of 2-O-glycerol ascorbic acid)

[0037] Under an argon atmosphere, add L-ascorbic acid and sodium bicarbonate to water, stir at room temperature for 30 minutes, and then add glycidol. Heat to 60°C and stir for 5 hours. Add methanol, filter, and concentrate the filtrate under reduced pressure. The resulting residue is subjected to silica gel column chromatography. Elute with chloroform / methanol / water = 6 / 4 / 1, and concentrate under reduced pressure to obtain 2-O-glycerol ascorbic acid.

[0038] (Synthesis of 2-O-glycerol-6-O-hexadecanoyl ascorbic acid)

[0039] Under an argon atmosphere, the synthesized 2-O-glycerol ascorbic acid was added to pyridine, and then n-hexadecanoic anhydride was added, and stirred at 60°C for 3 hours. Then, water was added and extracted with ethyl acetate. The extract was concentrated under reduced pressure, and 134 mg of the obtained residue was chromatographed on a silica gel column. Purification was performed by eluting with a mixed solution of chloroform / methanol / water = 7 / 3 / 0.3, and concentrated under reduced pressure to obtain 2-O-glycerol-6-O-hexadecanoyl ascorbic acid.

[0040] In the preparation of this embodiment, the concentration of the compound represented by the above formula (I) can be, for example, 0.001 mass % to 5.0 mass %, preferably 0.01 mass % to 2.0 mass %.

[0041] The above-mentioned content concentration has the advantage of being able to further improve atopic skin diseases.

[0042] The above-mentioned preparations usually contain water, and may contain a thickener, a surfactant, a preservative, etc. in addition to the above-mentioned ingredients.

[0043] The properties of the preparation of this embodiment are not particularly limited, and it is, for example, liquid. The preparation of this embodiment may be in a solid form.

[0044] The preparation of this embodiment can be prepared by a common method.

[0045] For example, the above-mentioned preparation can be prepared by mixing the components and stirring. A general stirring device can be used. If necessary, stirring can be performed while heating.

[0046] The above-mentioned preparation is preferably a skin external preparation (transdermal preparation) or a cosmetic. These skin external preparations or cosmetics are usually used by applying to the skin. The above-mentioned skin external preparations or cosmetics can be applied to, for example, the facial skin, the neck skin, the limbs skin, the scalp, the hair, or the mucous membranes of the nostrils, lips, ears, genitals, anus, etc. for use. In addition, the above-mentioned skin external preparations or cosmetics can be used as a bath agent or as a skin patch.

[0047] The preparation of the present embodiment is not necessarily limited to the classification of cosmetics, quasi-drugs, pharmaceuticals, etc. in the Medical Devices Act.

[0048] The atopic dermatitis improving agent, interleukin production inhibitor, and interleukin gene expression inhibitor of the present invention are as described above, but the present invention is not limited to the above-described embodiments. In addition, in the present invention, various forms used in general skin external compositions or oral compositions can be adopted within the scope of not impairing the effects of the present invention.

[0049] The technical solution disclosed in this specification includes the following contents.

[0050] (1) An atopic dermatitis improving agent comprising a glycerol ascorbic acid acylated derivative represented by the following formula (I).

[0051]

[0052] (2) An interleukin production inhibitor comprising the glycerol ascorbic acid acylated derivative represented by the above formula (I).

[0053] (3) An interleukin gene expression inhibitor comprising the glycerol ascorbic acid acylated derivative represented by the above formula (I).

[0054] (4) Use of the glycerol ascorbic acid acylated derivative represented by the above formula (I) for improving atopic dermatitis.

[0055] (5) Use of the glycerol ascorbic acid acylated derivative represented by the above formula (I) for inhibiting interleukin production.

[0056] (6) Use of the glycerol ascorbic acid acylated derivative represented by the above formula (I) for inhibiting interleukin gene expression.

[0057] (7) A method for treating atopic dermatitis, comprising applying a preparation containing a glycerol ascorbic acid acylated derivative represented by the following formula (I) to skin suffering from atopic dermatitis.

[0058] Example

[0059] Next, the present invention will be described in more detail with reference to Examples, but the present invention is not limited thereto.

[0060] (Test Example 1)

[0061] The preparation of each test example (which can be used as an external preparation for skin, for example) is prepared by dissolving 2-O-glycero-6-hexadecanoyl ascorbic acid (the compound represented by formula (I)) in a solvent such as water.

[0062] Note that the concentration was set to 10 μM, 20 μM, etc. each time.

[0063] (Test Example 2)

[0064] A preparation was prepared in the same manner as in Test Example 1 except that 2-O-glycero-6-dodecanoylascorbic acid was used instead of the compound represented by formula (I).

[0065] (Test Example 3)

[0066] A preparation was prepared in the same manner as in Test Example 1 except that 2-O-glycero-6-tetradecanoylascorbic acid was used instead of the compound represented by formula (I).

[0067] (Test Example 4)

[0068] A preparation was prepared in the same manner as in Test Example 1 except that 2-O-glycero-6-octadecanoylascorbic acid was used instead of the compound represented by formula (I).

[0069] (Test Example 5)

[0070] A preparation was prepared in the same manner as in Test Example 1 except that ascorbic acid was used instead of the compound represented by formula (I).

[0071] (Test Example 6)

[0072] A preparation was prepared in the same manner as in Test Example 1 except that ascorbyl palmitate was used instead of the compound represented by formula (I).

[0073] <Evaluation related to inhibition of cytokine production (in vitro test)>

[0074] Details of the in vitro experiments are as follows.

[0075] 6×10 4 Normal human epidermal keratinocytes (NHEK, manufactured by Kurabo Industries) were seeded into 12-well plates and cultured at 37°C and 5% CO2 for 72 hours. After removing the culture medium, it was replaced with a culture medium containing the following inflammatory stimulants (final concentration of 25 ng / mL) and each compound used in the above test example, and further cultured at 37°C and 5% CO2 for 3 hours. Then, according to the instruction manual of the product name "PureLink RNAMini kit" (invitrogen), total RNA was extracted from the cells, and the extracted RNA was reverse transcribed into cDNA using the test kit "ReverTra AceTM qPCR RT Master Mix (TOYOBO)". For the above cDNA, the IL-33 mRNA expression level was quantitatively evaluated by real-time PCR method. 3-Glyceraldehyde phosphate dehydrogenase (GAPDH) was used as an internal standard for correction.

[0076] The compound used in each test example was dissolved in dimethyl sulfoxide (DMSO) to prepare a stock solution, and then dissolved in a culture medium to a concentration of 10 to 20 μM. At this time, the concentration of DMSO was diluted to a concentration that did not cause cytotoxicity (1% or less).

[0077] ·Inflammatory stimulant (Phorbol 12-myristate 13-acetat) PMA

[0078] Negative control (NC without PMA added)

[0079] Positive control (steroid anti-inflammatory drugs)

[0080] (Dexamethasone) DEX, concentration 10 μM

[0081] Similarly, interleukin 1 alpha (IL-1 alpha) and interleukin 1 beta (IL-1 beta) were also evaluated.

[0082] For Test Examples 1 to 4, the graphs showing the in vitro test results of the evaluation related to the inhibition of the production of the above-mentioned cytokines are as follows: Figures 1 to 3 shown.

[0083] For Test Examples 1, 5, and 6, the graphs showing the in vitro test results for evaluating the inhibition of the production of the above-mentioned cytokines are as follows: Figures 4 to 6 shown.

[0084] from Figures 1 to 6 It was found that the preparation containing 2-O-glycero-6-hexadecanoylascorbic acid suppresses the expression of cytokine genes that are closely related to the aggravation of atopic skin diseases.

[0085] Therefore, the atopic dermatitis improving agent (interleukin production inhibitor and interleukin gene expression inhibitor) of the present embodiment can improve atopic dermatitis.

[0086] Industrial Availability

[0087] The atopic dermatitis improving agent of the present invention can be used, for example, as a skin external preparation or a cosmetic. The interleukin production inhibitor and the interleukin gene expression inhibitor of the present invention are applied to the skin, for example, to prevent and alleviate dry skin caused by atopic dermatitis, or to prevent and alleviate inflammatory skin roughness caused by atopic dermatitis. The atopic dermatitis improving agent of the present invention is applied directly to the stratum corneum, for example, and is suitable for use in pharmaceuticals, quasi-drugs, or cosmetics.

Claims

1. An atopic dermatitis improving agent comprising a glycerol ascorbic acid acylated derivative represented by the following formula (I).

2. An interleukin production inhibitor for inhibiting the production of interleukin 33 and interleukin 1, comprising a glycerol ascorbic acid acylated derivative represented by the following formula (I).

3. An interleukin gene expression inhibitor for inhibiting the expression of interleukin 33 and interleukin 1 genes, comprising a glycerol ascorbic acid acylated derivative represented by the following formula (I).